comprehensive -WSS

comprehensive

author：knowledge 2025-10-02 00:18:10 - browse：42811

Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally back?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the fallout over the FTC’s move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves an unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech VC with a very famous name.

For more on what we cover, here’s the FTC news; here’s more from Maze Therapeutics; here’s the Pfizer news; here’s the latest on Vertex; here’s the story behind its pain drug; here’s the Reed Jobs profile; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Smaller biotechs seek to piggyback on weight loss drug boom

WSS

This gene therapy has record $4.25 million price. It's saved children.

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

What Kate Middleton's cancer revelation might teach the world

Smaller biotechs seek to piggyback on weight loss drug boom

Health tech investors get more selective as pandemic boom fades

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

entertainment

comprehensive

focus

The high cost of giving birth even with insurance

Erich Jarvis studies song birds to learn about human stuttering

Cancer drug shortages should be causing more outrage

Questions loom on AstraZeneca cancer drug as safety concerns ebb

The high cost of giving birth even with insurance

Asbestos ban is immediate, but health effects will linger for decades

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

U.K. officials, researchers try to ease path for bespoke genetic treatments

Bright Health sells Medicare Advantage business to Molina

CRISPR technology availability, affordability needs to be expanded

hotspot

Merck, Daiichi strike cancer drug pact worth up to $22 billion

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Bring on the sabbaticals for nurses

Diabetes management: Digital health tools fall short, study says

UnitedHealth, Optum discontinue NaviHealth name

This gene therapy has record $4.25 million price. It's saved children.

leisure time

leisure time

hotspot

leisure time